Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Colorectal cancer is an aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the feasibility, safety and efficacy of neoadjuvant oxaliplatin, irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in patients with resectable colorectal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Collaborator: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Treatments: Camptothecin; Capecitabine; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• histologically verified colorectal cancer

• clinical stage T4N0-2M0、cT1-3N2M0 or M1(liver metastases only)

• age: 18-70 years

• ECOG 0-2

• adequate bone marrow, liver, renal and cardiac function (no history of ischemic heart disease)

• no prior cancer and/or chemotherapy

• signed informed consent

Exclusion Criteria:

• patients with a history of prior malignancy

• pregnant or lactating patients

• known or suspected brain metastasis